Amgen (AMGN) Long-Term Investments (2013 - 2014)
Amgen's quarterly Long-Term Investments came in at $3.4 billion in Q1 2014, little changed quarter-over-quarter from $3.4 billion in Q4 2013.
Amgen has reported Long-Term Investments for 2 years, with the latest figure at $3.4 billion in Q1 2014.
- For the quarter ending Q1 2014, Long-Term Investments changed N/A year-over-year to $3.4 billion; the trailing twelve-month figure through Mar 2014 stood at $3.4 billion (changed N/A YoY), and the FY2013 full-year result was $3.4 billion, changed N/A from the prior year.
- Long-Term Investments for Q1 2014 stood at $3.4 billion, roughly flat from $3.4 billion in the prior quarter.
- The five-year high for Long-Term Investments was $3.4 billion in Q1 2014, with the low at $3.4 billion in Q3 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 100.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.12 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 268.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 983.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 1.63 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 366.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 3.41 Bn |
| Dec 31, 2013 | 3.41 Bn |
| Sep 30, 2013 | 3.41 Bn |